Half-Year 2022 Financial and Clinical Trials Update

Hemophilia A franchise: Hemlibra new global standard of care 35% US/EU-5 patient share reached CHFM YoY CER growth Roche Isth 2022 CONGRESS JULY 9-13 ISTH2022 ORG LONDON 1,200 1,000 800 600 +59% 400 >500% 200 +58% Hemophilia Q2 update +31% • Nearly 18,000 patients treated globally 0 Q2 19 Q2 20 Q2 21 Q2 22 ■US Europe International Japan CER=Constant Exchange Rates . • Hemlibra continues to penetrate across all approved patient. segments ⚫ Ph III (HAVEN 6) strong data in mild/moderate patients presented at ISTH 2022 Outlook 2022 • US/EU: Further patient share gains in non-inhibitors • EU: Label expansion to include mild/moderate patients (HAVEN 6) expected ⚫ Ph III (HAVEN 7) in infants (0-1 year) interim results expected 26

View entire presentation